Close Menu

North America

The survey results point to the need for greater education among patients so they can better advocate for themselves.

The diversity of the organizations that have signed the letter to CMS demonstrates widespread concern over this policy.

City of Hope and Texas Oncology are the first customers for Trapelo, a decision support platform from Innovation Insights that involves labs and payors.

The latest guidelines include new language about screening individuals with BRCA mutations and the potential utility of certain biomarker tests.

The new multinational consortium, backed by the EU and Canada, seeks to improve understanding of immune responses and uncover new therapeutic targets.

The qPCR assay measures methylation of six genes and could help doctors identify aggressive vs indolent prostate cancer more accurately than PSA.

The researchers believe using cerebral spinal fluid will enable them to identify brain tumors with a higher sensitivity than with blood samples.

CMS's move to restrict coverage could limit test access for early-stage cancer patients and negatively impact lab revenues.

The firm's has expanded its ctDNA sequencing test to cover 17 genes, enough to provide a readout of microsatellite instability for guiding cancer immunotherapy use.

The new, multinational iReceptor Plus Consortium will develop a platform for sharing of AIRR-seq data to advance immunotherapy and precision medicine.

Pages